StockWatch
·
Biotechnology: Pharmaceutical Preparations
PatentNov 19, 2026, 08:59 AM

Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Filing

AI Summary

Clearmind Medicine Inc. announced the publication of a Hong Kong patent application for its psychedelic compounds targeting PTSD treatment. This application expands the company's global intellectual property portfolio, which is based on an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. The company aims to secure protection for its therapeutic candidates in major global markets, capitalizing on the growing PTSD therapeutics market, projected to reach $24.8 billion by 2030.

Key Highlights

  • Clearmind Medicine has published a Hong Kong patent application for psychedelic compounds aimed at treating PTSD.
  • The patent application is part of an exclusive worldwide licensing agreement with Yissum Research Development Company.
  • The compounds were invented by Professors Ahmed Masaewa, Rami Yaka, and Avi Priel of the Hebrew University.
  • Clearmind holds exclusive global rights to develop, manufacture, and commercialize these novel compounds.
  • The global PTSD therapeutics market was valued at approximately $19 billion in 2025 and is projected to reach $24.8 billion by 2030.
  • The PTSD pharmaceutical market across seven major markets is projected to grow from $1.2 billion in 2024 to $5.5 billion by 2034.